Faculty David M. Pariser, MD Professor Eastern Virginia Medical School Norfolk, VA
|
|
- Briana Anderson
- 5 years ago
- Views:
Transcription
1
2 Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Creative Educational Concepts or the supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
3 Usage Rights This slide deck is provided for educational purposes and slides may be used for personal, non-commercial presentations only as long as content and references remain the same. No part of this slide deck may be published or distributed in print or electronic format without prior written permission from Creative Educational Concepts.
4 Learning Objectives Analyze the pathogenesis of psoriasis, focusing on the inflammatory cascade and corresponding therapeutic targets for traditional non-biologic systemic agents as well as novel biologic therapies in development. Explore current treatment paradigms for psoriasis using traditional biologic agents and examine potential place in therapy for newer emerging biologic therapies, appraising the predicted benefits of these emerging agents based on novel therapeutic targets. Using real-world, case-based patient scenarios, effectively integrate strategies and develop treatment plans for patients with psoriasis that address practical issues in the use of traditional biologic agents, and potential place in therapy for emerging biologic agents
5 Faculty David M. Pariser, MD Professor Eastern Virginia Medical School Norfolk, VA Please refer to your handout for a full list of disclosures.
6
7 Psoriasis: Clinical Decision Making for the Nurse Practitioner Complete skin and joint assessment Diagnosing Initiating therapy Managing patient over time Adjusting therapy Monitoring for adverse events and comorbidities
8 Limited Forms of Psoriasis
9 Widespread Plaque Psoriasis
10 Dermatology s New View on Psoriasis 1 o skin disorder 20 years Immunologic dysfunction
11 Healthy Skin Immunology of Psoriasis Injury or Inflammation Steady-state Immunity (tolerance) Immune Amplification (active effector immunity) Lowes MA, et al. Annu Rev Immunol
12 Clinical and Histological Picture Non-Lesional Lesional Lowes MA, et al. Annu Rev Immunol
13 Increasing Risk Prior Treatment Paradigm Process: Psoriasis therapy followed stepwise progression Patients must fail the previous step of therapy before initiating a more aggressive therapy OTC Products Emollients Other Rx Topical Agents Topical steroids Vitamin D analogs Topical retinoids Other Rx topicals Phototherapy UVB Broadband UVB Narrowband PUVA Laser Systemic Therapy Cyclosporine Methotrexate Acitretin Systemic steroids Order of Treatment Progression Lebwohl M, et al. J Am Acad Dermatol
14 Shifting the Treatment Paradigm Treatment Toolbox for Moderate to Severe Disease Topicals for mild disease Phototherapy Laser PUVA UVB Systemic Agents Acitretin Apremilast Cyclosporine Methotrexate Biologic Agents Adalimumab Etanercept Infliximab Secukinumab Ustekinumab
15 Who Says So? AAD Consensus Statement on Psoriasis Therapies (J Am Acad Dermatol, November, 2003): Systemic therapy may be considered for patients with psoriasis on the palms, soles, head and neck, genitalia or when 5% or more of skin surface is involved Biologics should be considered among the first-line treatment options in a patient who is a candidate for systemic therapy AAD=American Academy of Dermatology Callen JP, et al. J Am Acad Dermatol
16 Determining Severity Pariser, et al. (2007) NPF Med Ad Board Consensus on Disease Severity This clinical consensus statement proposes a 2-tiered system for plaque psoriasis therapy that reflects more accurately than the current system how patients are treated in clinical practice. American Academy of Dermatology Work Group, et al. (2011) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. The severity of psoriasis is defined not only by extent of body surface area (BSA) involvement (<5% being considered mild, 5% but <10% moderate, and 10% severe), but also by involvement of the hands, feet, facial, or genital regions, by which, despite involvement of a smaller BSA, the disease may interfere significantly with activities of daily life. NPF=National Psoriasis Foundation Pariser DM, et al. Arch Dermatol. 2007; Menter A, et al. J Am Acad Dermatol
17 When to Select a Systemic Effective and manageable risk if used correctly Variable cost to patient Not all are candidates for biologic therapy Biologic therapies may fail as monotherapy, and succeed in combination with systemics Rescue therapies in tough clinical scenarios Options Methotrexate, Cyclosporine (CyA), Acitretin, Apremilast
18 Percentage of Patients Methotrexate and Cyclosporine: PASI 75 Response at Week % 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Double-blind, active-controlled (no placebo) Dose adjustments allowed for each drug 71% Cyclosporine (N=42) Dose mg/kg 60% Methotrexate (N=43) Dose mg/kg Vera MR, et al. N Engl J Med
19 Percentage of Patients Responding Methotrexate Efficacy vs. Infliximab For all visits: P< Weeks Infliximab (N=653) MTX (N=215) PASI 75 response by visit (intent-to-treat population). Patients achieving <PASI 50 by Week 16 (grey line) were permitted to switch treatment groups MTX=methotrexate Barker J, et al. Br J Dermatol
20 Area-Severity Index Cyclosporine: Dose Dependent Efficacy Fixed-Dose Phase Adjusted-Dose Phase Week of Study Placebo 3 mg/kg/day 5 mg/kg/day 7.5 mg/kg/day Solid symbols indicate significantly different values vs. before treatment (week 0) (P<.005) All groups receiving cyclosporine had significant improvement vs. placebo (P<.001) The groups receiving 5 mg/kg/day and 7.5 mg/kg/day had significant improvement vs. the group receiving 3 mg/kg/day (P<.01) but not as compared with each other (P>.4) Ellis CN, et al. N Engl J Med
21 Acitretin % BSA Involvement Reduction Group Double-Blind Daily Dose, mg Open-Label Daily Dose, mg Mean % BSA % BSA Reduction at Week 8 % BSA Reduction at Week 24 (N=19) 25 (Lo) (N=52) 25 (Lo) (N=23) 50 (Hi) (N=77) 50 (Hi) Placebo (N=101) 0 (mean, 43) (worse disease) 43 Mean % BSA involvement at baseline. After DBL phase, placebo patients were allowed into open-label phase to receive treatment. Haushalter K, et al. J Dermatolog Treat
22 Limitations of Conventional Systemic Therapies Agent Adverse Event Contraindications Methotrexate Cyclosporine Acitretin Hepatotoxicity, drug interactions, immunosuppression, bone marrow suppression, pneumonitis, birth defects, decreased sperm count, miscarriage Immunosuppression, impaired renal function, hypertension, malignancies, drug interactions Birth defects, mucocutaneous effects, dyslipidemia Pregnancy (category X) a, breastfeeding, renal impairment, hepatitis, cirrhosis, leukopenia, thrombocytopenia, regular alcohol use, unreliability in patients Acute infections, active malignancies, uncontrolled hypertension, impaired renal function Pregnancy b, breastfeeding a Rule out pregnancy in women of childbearing potential; avoid pregnancy if either partner is receiving methotrexate; contraception: women, during therapy and at least 1 ovulatory cycle afterward; men, at least 3 months after therapy. b Patients should not become pregnant for at least 3 years following drug discontinuation. Menter A, et al. J Am Acad Dermatol
23 Advantages of Conventional Systemic Therapies Agent Methotrexate Cyclosporine Acitretin Advantages Fast acting Good efficacy Effective in psoriasis and psoriatic arthritis FDA approved for psoriasis and psoriatic arthritis Long track record in rheumatoid arthritis Combination data available with biologics Least expensive Very fast acting Very high efficacy FDA approved for psoriasis and psoriatic arthritis Long track record in rheumatoid arthritis and Crohn s disease Pregnancy class B Oral agent Side effects not serious and manageable Use in pustular psoriasis Hands and feet Pathirana D, et al. J Eur Acad Dermatol Venereol. 2009; Menter A, et al. J Am Acad Dermatol
24 Small Molecules
25 Apremilast Novel, oral small molecule Inhibits PDE-4 Anti-inflammatory properties Reduces TNF-α, IL-2, IFN-γ, several leukotrienes and NO synthase Recently FDA approved for PsA and PsO in adult patients with moderate to severe plaque No recommended laboratory or TB monitoring PDE-4=phosphodiesterase-4; PsA=psoriatic arthritis; PsO=psoriasis; TB=tuberculosis Reich K, et al. Presented at AAD Annual Meeting; 2013.
26 Apremilast Mechanism of Action Reich K, et al. Presented at AAD Annual Meeting; 2013.
27 Patients Achieving PASI 75 (%) Apremilast Phase III (ESTEEM 1): PASI 75 by Prior Treatment Experience at Week N= Overall LOCF, Full Analysis Set (N=844) No Prior Systemic No Prior Biologic P<.0001; P=.0273 vs. placebo. Conventional +/or biologics. Prior Biologic Placebo Apremilast 30 mg BID Failed Prior TNF Reich K, et al. Presented at AAD Annual Meeting; 2013.
28 Apremilast Phase III (ESTEEM 1): AEs in 5% of Any Treatment (Weeks 0-16) Adverse Event (AE) N(%) Placebo (N=282) Apremilast 30 mg BID (N=560) Diarrhea 20(7.1) 105(18.8) Nausea 19(6.7) 88(15.7) URTI 21(7.4) 57(10.2) Nasopharyngitis 23(8.2) 41(7.3) Tension headache 12(4.3) 41(7.3) Headache 13(4.6) 31(5.5) >96% of patients had mild/moderate or no AEs. 1 (0.4%) placebo and 2 (0.4%) apremilast 30 mg twice daily patients reported severe diarrhea or nausea. Diarrhea includes loose stools and increased urgency. URTI=upper respiratory tract infection Reich K, et al. Presented at AAD Annual Meeting; 2013.
29 Patient Case
30 Case 27 year old female, psoriasis onset early 20sbetter but never clear or comfortable with topical agents Only health issue- 5 3 and 185 lbs Strong family history of psoriasis CyA used to quickly clear her for her wedding with transition to adalimumab 90% clear for 2 years-became pregnant Elected not to discontinue while pregnant Moved to East Coast in first trimester
31 Returned to Dallas Case-Updated History East Coast Derm withheld adalimumab throughout first pregnancy-topicals helped miminally Post-partum flare-started on etanercept, some improvement, another pregnancy, held drug until post-partum flare then moved back to Dallas Presented with very inflammatory, pruritic large plaques almost 30% BSA, no arthralgia Restarted adalimumab-regained 75% clearance
32
33 Case Continued Adalimumab less effective than first experience Options: Continue, increase dose, add another agent, or change biologics Ustekinumab 45 mg utilized Better, not clear, with flare 1-2 weeks pre-dosing, occasional hand stiffness and tender joints Options: Continue, increase dose, decrease interval, add another agent, or change biologics
34 Better but Flares Pre-Dosing
35 Better vs. Almost Clear vs. Clear Should we consider combination therapy (adding methotrexate or apremilast) or changing biologic agents? Can we get her closer to PASI 90 or 100? Does it matter?
36 Case Current Treatment Plan Secukinumab was presented as an option as monotherapy with continuation of current regimen until new drug approved OR increase dose of ustekinumab to 90 mg every 12 weeks OR decrease interval to every 8 week dosing Patient elected to attempt dosing at every 8 week interval if approved, if not, we will transition to secukinumab
37 When to Select a Biologic Patient needs more effective therapy (MTX, CyA, Acitretin) not an option Previous sub-optimal experience ( failure ) Contraindication Phototherapy not an option Unavailability or inconvenient Cost prohibitive Failure or risk of skin cancer Pathirana D, et al. J Eur Acad Dermatol Venereol. 2009; Menter A, et al. J Am Acad Dermatol. 2008; Menter A, et al. J Am Acad Dermatol
38 Which Biologic to Select Self injectable vs. in office injection or infusion Rapid onset of therapeutic effect needed Prior biologic use Medical history and concomitant illnesses Arthralgia Malignancy history or risk Infection-TB Multiple sclerosis or other demyelinating disease Congestive heart failure And, unfortunately Provider comfort level Insurance formulary status Patient copayments Pathirana D, et al. J Eur Acad Dermatol Venereol. 2009; Menter A, et al. J Am Acad Dermatol. 2008; Menter A, et al. J Am Acad Dermatol
39 T-Cell Inhibitors 1st Generation Biologics
40 Screening Prior to Starting a Biologic Initial Assessment of Immunization Status or Disease History Haemophilus influenzae Diphtheria Tetanus Pertussis Varicella zoster Hepatitis A and B Human papillomavirus Influenza Herpes Zoster MMR Meningococcal Streptococcus pneumoniae TNF-α blockers: Adalimumab, Etanercept, Infliximab Complete blood cell count + platelets: baseline and every 2-6 months Chemistry screen + LFT: baseline and every 2-6 months TB skin test: baseline and annually thereafter Ustekinumab TB skin test: baseline Lebwohl M, et al. J Am Acad Dermatol. 2008; Wine-Lee L, et al. J Am Acad Dermatol. 2013; FDA Prescribing Information.
41 Cytokines and Cytokine Inhibitors in Chronic Inflammation TNF-α IL-1 IFN- IL-8 GM-CSF IL-12 IL-23 Others Pro-inflammatory Adalimumab Etanercept Infliximab Golimumab IL-15 IL-16 IL-17 IL-18 IL-22 TGFβ IL-6 2 nd Generation Biologics IL-1RA sil-1r1 stnf-ri,ii IL-4 IL-10 IL-11 IL-13 IL-18BP Anti-inflammatory Sabat R, et al. Exp Dermatol
42 % Patients Adalimumab Phase III: PASI 75 Response Weeks 0 24 Placebo (N=398) Adalimumab (N=814) Week 4 Week 8 Week 12 Week 16 Week 24 Note: Intention-to-Treat (ITT), patients with missing PASI scores considered non-responders P<.001 adalimumab vs. placebo Menter A, et al. J Am Acad Dermatol
43 PASI 75 Response (% of Patients) Methotrexate Efficacy vs. Adalimumab Placebo Methotrexate Adalimumab # Week 4 Week 8 Week 12 Week 16 # P=.001 adalimumab vs. placebo; P<.001 adalimumab vs. placebo P<.001 adalimumab vs. methotrexate. Note: ITT: pts with missing PASI scores considered non-responders Saurat JH, et al. Br J Dermatol
44 % Patients Etanercept: PASI 75 at 12 Months Etanercept 25 mg BIW Etanercept 50 mg --> 25 mg Etanercept 50 BIW Intent to Treat, LOCF mg BIW mg 25 mg BIW 60% 45% 20 As Treated Weeks BIW=twice weekly; LOFC=last observation carried forward Sterry W, et al. Presented at EADV Annual Congress; 2004; Papp KA. Arch Dermatol Res
45 % Patients Infliximab: PASI 75 Over Time 100 Infliximab 5 mg/kg Non-Responder Imputation Dropouts for lack of efficacy=tx Failure Missed data points=tx Failure Conservative view of data Weeks Reich K, et al. Lancet
46 Cytokines and Cytokine Inhibitors in Chronic Inflammation Tildrakizumab Gesulkumab TNF-α IL-1 IFN- IL-8 GM-CSF IL-12 IL-23 Others Pro-inflammatory Ustekinumab Briakinumab IL-15 IL-16 IL-17 IL-18 IL-22 TGFβ IL-6 Secukinumab Ixekizumab Brodalumab 3 rd Generation Biologics IL-1RA sil-1r1 stnf-ri,ii IL-4 IL-10 IL-11 IL-13 IL-18BP Anti-inflammatory Sabat R, et al. Exp Dermatol
47 Agents Targeting Interleukins Ustekinumab IL-12, IL-23 IL-17A Secukinumab Ixekizumab Brodalumab IL-23 Tildrakizumab Gesulkumab
48 Psoriasis: Targeting the IL-12/23 Pathway IFNγ Th1 IL-2 APC TNF-β Th17 Th22 IL-17a IL-17f IL-6 TNF-α IL-21 IL-22 Fitch E, et al. Curr Rheumatol Rep. 2007; Romagnani S. Inflamm Bowel Dis
49 The p40 Subunit is Shared IL-12 IL-23 p40 p35 p19 p40 Ustekinumab NK or T cell membrane Leonardi CL, et al. Lancet. 2008; Papp KA, et al. Lancet
50 When to Select an IL-12/23 Biologic First-line for any moderate to severe adult patient with psoriasis that is a candidate for a systemic agent or phototherapy Also approved for PsA Inadequate response to systemic or TNF inhibitor Dosing schedule or in office injections preferred
51 Percent of Patients Phoenix 1 & 2: PASI 75 Response at Week PHOENIX PHOENIX Placebo N=255 Ustekinumab 45 mg N=255 Ustekinumab 90 mg N=256 4 Placebo N=410 Ustekinumab 45 mg N=409 Ustekinumab 90 mg N=411 P<.001 vs. placebo Leonardi CL, et al. Lancet. 2008; Papp KA, et al. Lancet
52 Percent of Patients Ustekinumab Phase III PASI Response Over 28 Weeks PHOENIX 1 Week PHOENIX 2 Week PASI 50 PASI 75 PASI 90 0 PASI 50 PASI 75 PASI 90 Ustekinumab 45 mg (N=250) Ustekinumab 90 mg (N=243) Ustekinumab 45 mg (N=397) Ustekinumab 90 mg (N=400) P<.001 vs. placebo for all comparisons Leonardi CL, et al. Lancet. 2008; Papp KA, Lancet
53 Function of Th17 Effector Cytokines IL-17a Expressed by memory T cells and NK cells Increased in psoriatic skin Subcutaneous injection neutrophilia Enhances inflammation Enhances angiogenesis Fitch E, et al. Curr Rheumatol Rep IL-22 Expressed in high levels by Th17 cells Increased in psoriasis (skin and plasma) Levels correspond to disease activity Induces keratinocyte hyperproliferation (in vivo, in vitro) Stimulates keratinocytes to secrete antimicrobial peptides
54 Percent of Subjects Secukinumab Phase III Psoriasis Results ERASURE Results PASI 75 and IGA 0/1 Through 52 Weeks (1/2) PASI 75 Response Secukinumab 300 mg Secukinumab 150 mg IGA 0/1 Response Secukinumab 300 mg Secukinumab 150 mg Placebo Placebo Week Week Secukinumab 150 mg (N=245) Secukinumab 300 mg (N=245) Placebo (N=247) IGA=investigator s global assessment Langley RG, et al. N Engl J Med
55 Secukinumab: Phase II Safety Results Preferred Term 1x25 mg N=29 N(%) Secukinumab 3x25 mg N=26 N(%) 3x75 mg N=21 N(%) 3x150 mg N=27 N(%) Placebo N=22 N(%) Patients with any AE(s) 22(75.9) 19(73.1) 16(76.2) 24(88.9) 16(72.7) Death (4.5) Serious Adverse Events (SAEs) 0 2(7.7) 1(4.8) 0 2(9.1) AEs leading to discontinuation 0 1(3.8) 0 1(3.7) 0 AEs and infections 5% in any treatment group Psoriasis (worsening) 8(27.6) 4(15.4) 4(19.0) 3(11.1) 2(9.1) Nasopharyngitis 1(3.4) 4(15.4) 4(19.0) 4(14.8) 2(9.1) Pharyngitis 0 1(3.8) 0 2 (7.4) 0 Upper respiratory tract infection 3(10.3) 2(7.7) 1(4.8) 2(7.4) 0 Headache 1(3.4) 2(7.7) 1(4.8) 1(3.7) 0 Pruritus 1(3.4) 0 0 1(3.7) 3(13.6) Respiratory tract infection, viral 1(3.4) 1(3.8) 1(4.8) 0 2(9.1) Papp KA, et al. Br J Dermatol
56 Secukinumab: Phase II Safety Results Secukinumab Preferred Term 1x25 mg N=29 N(%) 3x25 mg N=26 N(%) 3x75 mg N=21 N(%) 3x150 mg N=27 N(%) Placebo N=22 N(%) Other AEs of interest Atrial fibrillation 0 1(3.8) 0 0 1(4.5) Acute myocardial infarction (4.5) Arrhythmia 1(3.4) Cardiac failure, congestive 0 1(3.8) Cardiomyopathy 0 1(3.8) Myocardial infarction (4.5) Wolff-Parkinson-White syndrome 0 0 1(4.8) 0 0 Papp KA, et al. Br J Dermatol
57 Percent Improvement in PASI Score Brodalumab: Phase II Efficacy Results Percent Improvement in PASI Scores over Time Week All P<.001 vs. placebo and vs. 70 mg dose of brodalumab P<.001 vs. placebo 210 mg Brodalumab group 140 mg Brodalumab group 280 mg Brodalumab group 70 mg Brodalumab group Placebo group The P value for the comparison of the 70 mg dose of brodalumab with placebo (P<.001) is for all the time points except week 2, for which the P value was.002. PASI denotes psoriasis-area-and-severity index. Papp KA, et al. N Engl J Med
58 Brodalumab: Phase II Safety Results Variable Placebo Brodalumab Adverse events (N=37) 70 mg (N=38) 140 mg (N=39) 210 mg (N=40) Number of Patients(Percent) 280 mg (N=41) Total (N=158) Any 23(62) 26(68) 27(69) 33(82) 30(73) 116(73) Serious 1(3) 1(3) 0 1(2) 0 2(1) Leading to withdrawal from study (2) 1(1) Leading to discontinuation of study drug 1(3) 0 0 2(5) 1(2) 3(2) Grade 3, 4, or 5 2(5) 1(3) 1(3) 3(8) 2(5) 7(4) Common adverse events Nasopharyngitis 3(8) 6(16) 1(3) 4(10) 2(5) 13(8) Upper respiratory tract infection 2(5) 3(8) 3(8) 2(5) 5(12) 13(8) Arthralgia 1(3) 1(3) 2(5) 0 4(10) 7(4) Injection-site erythema 1(3) 1(3) 1(3) 3(8) 4(10) 9(6) Pain in extremity 0 1(3) 0 3(8) 4(10) 8(5) Nausea 1(3) 4(11) 1(3) 1(2) 0 6(4) A serious adverse event was defined as an event that was fatal or life threatening, required or prolonged hospitalization, or caused persistent or substantial disability or incapacity or a congenital anomaly or birth defect or an event that was considered by the investigator to be a medically important event. The severity of adverse events was graded according to the National Cancer Institute s Common Terminology Criteria for Adverse Events, version 4.0. Common adverse events were those that were reported in at least four patients in any treatment group. Papp KA, et al. N Engl J Med
59 Subjects Achieving a PASI Response (% With 95% CI) Results: PASI 75/90/100 in Subjects Treated With Brodalumab from Parent Study Baseline, Observed Data 100 PASI 75 PASI 90 PASI N=173 N=175 N=175 N=175 N=175 N=172 N=168 N=169 N=165 N=159 N= Weeks N=number of subjects who were treated and had an assessment at the specified visit As observed analysis 165 subjects remained on study at week 48 (48 on 140 mg; 117 on 210 mg); 153 remained on study and had an assessment at week 96 (105 on 140 mg; 48 on 210 mg) Papp KA, et al. N Engl J Med
60 Patients (%) Ixekizumab: Phase II Efficacy Results Patients (%) Placebo (N=26) 10 mg Ixekizumab (N=28) 25 mg Ixekizumab (N=30) 75 mg Ixekizumab (N=29) 150 mg Ixekizumab (N=28) 75% Reduction in PASI Score 90% Reduction in PASI Score mg 75 mg 25 mg 10 mg mg 75 mg 25 mg 10 mg Weeks Placebo Weeks Placebo Leonardi C, et al. N Engl J Med
61 Patients (%) Ixekizumab: Phase II Efficacy Results Patients (%) Placebo (N=26) 10 mg Ixekizumab (N=28) 25 mg Ixekizumab (N=30) 75 mg Ixekizumab (N=29) 150 mg Ixekizumab (N=28) 100% Reduction in PASI Score spga Score of 0 or mg 75 mg 25 mg mg 25 mg 75 mg 10 mg Weeks 10 mg Placebo Weeks Placebo Leonardi C, et al. N Engl J Med
62 Ixekizumab: Phase II Adverse Events Adverse Events during the Study Period (through 20 Weeks), According to Study Group. Variable Placebo (N=27) 10 mg (N=28) 25 mg (N=30) 75 mg (N=29) 150 mg (N=28) No. of adverse events No. of serious adverse events Adverse events-no. patients (%) 17(63) 21(75) 21(70) 17(59) 13(46) Adverse events-no. of patients (%) Infection or infestation 7(26) 12(43) 9(30) 9(31) 8(29) Nasopharyngitis 5(19) 3(11) 3(10) 3(10) 4(14) Upper respiratory infection 1(4) 1(4) 3(10) 1(3) 1(4) Injection-site reaction 0 0 3(10) 1(3) 2(7) Headache 1(4) 4(14) 4(13) 1(3) 1(4) Allergy or hypersensitivity 2(7) 1(4) 1(3) 2(7) 1(4) Adverse events were those that first occurred or worsened after randomization. The specific events listed are those that occurred in at least 5% of patients receiving ixekizumab. Allergy or hypersensitivity was defined as that distinct from injection-site reactions. Allergy or hypersensitivity events include those described by reported terms that were consistent with hypersensitivity on the basis of Medical Dictionary for Regulatory Activities Standard Medical Queries for anaphylactic reaction, angioedema, and severe cutaneous adverse reaction. Leonardi C, et al. N Engl J Med
63 Tildrakizumab
64 Selectively Targeting IL-23 The p19 Subunit is NOT Shared IL-12 IL-23 p40 p35 p19 p40 NK or T cell membrane
65 % Patients Tildrakizumab: Phase IIb Psoriasis Trial 100 PASI 75 at 16 Weeks 100 PASI 90 at 16 Weeks PBO 5 mg 25 mg 100 mg 200 mg PBO 5 mg 25 mg 100 mg 200 mg N=41 N=40 N=87 N=88 N=84 N=45 N=42 N=90 N=87 N=86 Note: ITT-NRI analysis P.001 vs. placebo Thaci D, et al. Presented at EADV Annual Congress; 2013.
66 Tildrakizumab: Phase IIb Psoriasis Trial Adverse Events 5% in Any Treatment Group [N(%)] 5 mg (N=42) 25 mg (N=91) 100 mg (N=89) 200 mg (N=86) PBO (N=45) Any AE 30(71) 55(60) 56(63) 53(62) 31(69) Lymphadectomy 2(5) 3(3) 2(2) 1(1) 0 Diarrhea 1(2) 3(3) 6(7) 3(3) 3(7) Dyspepsia 2(5) 1(1) 2(2) 0 0 Toothache 2(5) 1(1) 1(1) 2(2) 1(2) Bronchitis 3(7) 3(3) 1(1) 0 2(4) Gastroenteritis 2(5) 0 3(3) 3(3) 1(2) Nasopharyngitis 8(19) 12(13) 13(15) 10(12) 9(20) URTI 2(5) 0 3(3) 2(2) 0 Arthralgia 2(5) 2(2) 0 2(2) 0 Back pain 1(2) 4(4) 3(3) 4(5) 0 Musculoskeletal pain 2(5) 4(4) 1(1) 2(2) 0 Headache 3(7) 5(5) 5(6) 7(8) 4(9) Cough 3(7) 2(2) 2(2) 1(1) 2(4) Pruritus 1(2) 4(4) 0 4(5) 4(9) Urticaria 2(5) 0 1(1) 0 0 Hypertension 0 2(2) 2(2) 4(5) 0 Papp KA, et al. Presented at AAD Annual Meeting; 2013.
67 CP-690,550 (Tofacitinib) Janus Kinase (JAK) Inhibitor Inhibits JAK 1 and 3 >JAK 2 Rheumatoid Arthritis inflammatory cytokines, chemokines inflammatory cells (Mf, T cells, NK and NKT cells) Recently approved by US-FDA (November 2012) Psoriasis 5 mg twice daily Highly efficacious Relatively well tolerated Papp KA, et al. Br J Dermatol. 2012; Mamolo C, et al. J Eur Acad Dermatol Venereol
68 PASI 75 Response Rate (%) Tofacitinib: PASI 75 Results Over Time 100 Placebo Tofacitinib 5 mg BID Tofacitinib 2 mg BID Tofacitinib 15 mg BID Baseline Week Papp KA, et al. Br J Dermatol
69 Therapeutic End Points in Psoriasis: Why PASI 90 and PASI 100 Matter
70
71 Mean % PASI Estimated Probabilities of Response The positions of ustekinumab 45 mg and ustekinumab 90 mg are reversed when the ustekinumab data are analyzed according to the dosing recommendations listed in the Summary of Product Characteristics (eg 45 mg in patients <100 kg and 90 mg in patients >100 kg). Reich K, et al. Br J Dermatol
72 Mean % PASI Estimated Probabilities of Response The positions of ustekinumab 45 mg and ustekinumab 90 mg are reversed when the ustekinumab data are analyzed according to the dosing recommendations listed in the Summary of Product Characteristics (eg 45 mg in patients <100 kg and 90 mg in patients >100 kg). Reich K, et al. Br J Dermatol
73 Mean % PASI Estimated Probabilities of Response The positions of ustekinumab 45 mg and ustekinumab 90 mg are reversed when the ustekinumab data are analyzed according to the dosing recommendations listed in the Summary of Product Characteristics (eg 45 mg in patients <100 kg and 90 mg in patients >100 kg). Reich K, et al. Br J Dermatol
74
75
76
77
78 Clear is Better Than Almost Clear Reported DLQI indicating treatment failure 20% in patients with Almost Clear skin 2% in patients with Clear skin DLQI=Dermatology Life Quality Index Takeshita J, et al. J Am Acad Dermatol
79 If it becomes realistic to clear most patients with psoriasis...does everyone deserve to be clear?..and at what cost?
80
81
82
The New and Emerging Agents: Dermatology
Psoriasis Treatment 2013: What is New and on the Horizon? Neil J Korman, MD, PhD Professor of Dermatology University Hospitals Case Medical Center Clinical Director Murdough Family Center for Psoriasis
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationHealth Related Quality of Life: The Impact of Psoriasis When Designing Tailored Treatment Plans
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of October 2015. The content and views presented in this educational activity are those of
More informationBreakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationBiologics in Psoriasis: 2018 and Beyond. Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research
Biologics in Psoriasis: 218 and Beyond Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Biologics in Psoriasis FDA approved TNF inhibitors Etanercept Adalimumab
More informationTHE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS Mădălina FRÎNCU 1 Abstract: Biological
More informationAnti-TNF biologic agents Dr Lluís Puig
Department of Dermatology Hospital de la Santa Creu i Sant Pau IPC NOVARTIS PSORIASIS PRECEPTORSHIP Anti-TNF biologic agents Dr Lluís Puig Barcelona, July 9th-10th, 2013 Anti-TNF therapy in the pathophysiology
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationBioavailability 55% - 77%
Brand Name: Cosentyx Generic Name: secukinumab Manufacturer 1 : Novartis Pharmaceuticals Corporation Drug Class 2,3 : Antipsoriatic Agent, Interleukin-17A Receptor Antagonist Uses: Labeled Uses 1,2,3 :
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationBilaga 1.till rapport. Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies
Bilaga 1.till rapport Ljusbehandling och systemisk behandling av psoriasis, rapport nr 278 (2018) Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies Description of included
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationWhat's Now, What's Next: Individualizing the Treatment of Patients With Moderate to Severe Psoriasis for the Dermatologist Presentation 1
The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants from Celgene
More informationUSTEKINUMAB and BRIAKINUMAB
USTEKINUMAB and BRIAKINUMAB Andrew Blauvelt, M.D. Professor, Dept. of Dermatology and Dept. of Molecular Microbiology & Immunology Oregon Health & Science University Chief, Dermatology Service Veteran
More informationIs Apremilast (Otezla) Effective in Reducing Pruritus in Adults over 18 Years Old with Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 3-2017 Is Apremilast (Otezla) Effective in
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationClinical Policy: Brodalumab (Siliq) Reference Number: CP.PHAR.375 Effective Date: Last Review Date: 05.18
Clinical Policy: (Siliq) Reference Number: CP.PHAR.375 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationKim A. Papp, MD PhD Probity Medical Research, Waterloo, ON, Canada
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pooled Efficacy Results from the Subgroup of Canadian Patients in Two Phase III Randomized Controlled
More informationElements of Successful PBS Applications. Barbara Radulski RN. Copyright
Elements of Successful PBS Applications Barbara Radulski RN PBS Requirements April 1 2006 THE RULES PBS Requirements 18 years and over Psoriasis x 6 months Failed to achieve an adequate response to 3 systemic
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationBiologics and Psoriasis: The Beat Goes On
Biologics and Psoriasis: The Beat Goes On Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is
More informationDisclosures. Activity Information. Updates in Psoriasis Therapy. Ustekinumab Guselkumab Tildrakizumab. Secukinumab Ixekizumab Brodalumab
Disclosures Faculty: Teri Greiling, MD, PhD, has disclosed the following conflicts of interest: research funding: Eli Lilly. Updates in Psoriasis Therapy 12 October 2018 St. Charles Medical Center Teri
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368
Apremilast for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta368 NICE 2015. All rights reserved. Contents 1 Guidance...
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationRisankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis
NIHR Innovation Observatory Evidence Briefing: November 2017 Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis NIHRIO (HSRIC) ID: 9708 NICE ID: 9191 LAY SUMMARY Plaque
More informationDERMATOLOGY. The Changing Landscape of Psoriasis Treatment ABSTRACT
WHITE PAPER PRESENTED BY PREMIER RESEARCH The Changing Landscape of Psoriasis Treatment ABSTRACT Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis, with more
More informationIL-17 and IL-23 antagonists
IL-17 and IL-23 antagonists Prof. Jonathan Barker 1 Key T cell subsets and biologic therapies in psoriasis Girolomoni G, et al. JEADV 2017 2 MoA of biologics targeting T cell pathways p35 IL-12 p40 Ustekinumab
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18
Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationHorizon Scanning Centre January Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652
Horizon Scanning Centre January 2013 Apremilast for psoriasis SUMMARY NIHR HSC ID: 2652 This briefing is based on information available at the time of research and a limited literature search. It is not
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 11.18
Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPsoriasis. Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement
Psoriasis Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement Copyright 2017 by Sea Courses Inc. All rights reserved. No part
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationEffect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial
1152 Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial April W. Armstrong, MD, MPH 1 ; Christopher E.M. Griffiths, MD 2 ; Tom
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1097-7 Program Prior Authorization/Notification Medication *Stelara (ustekinumab) *This program applies to the subcutaneous formulation
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17
Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAdalimumab M Clinical Study Report Final R&D/14/1263. Page:
Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:
More informationContemporary Management of Moderate to Severe Plaque Psoriasis
SUPPLEMENT THE AMERICAN JOURNAL OF MANAGED CARE December 2017 Vol. 23 No. 21, Sup. Contemporary Management of Moderate to Severe Plaque Psoriasis HIGHLIGHTS Effect of Plaque Psoriasis on Physical, Cardiovascular,
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ustekinumab_stelara 02/2010 10/2018 10/2019 10/2018 Description of Procedure or Service Plaque psoriasis
More informationPharmacy Medical Necessity Guidelines: Stelara (ustekinumab)
Pharmacy Medical Necessity Guidelines: Effective: November 14, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd.
ixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd. 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationTremfya (guselkumab) NEW PRODUCT SLIDESHOW
Tremfya (guselkumab) NEW PRODUCT SLIDESHOW Introduction Brand name: Tremfya Generic name: Guselkumab Pharmacological class: Interleukin-23 antagonist Strength and Formulation: 100mg/mL; soln for SC inj;
More informationSubject: Guselkumab (Tremfya ) Injection
09-J2000-87 Original Effective Date: 09/15/17 Reviewed: 09/12/18 Revised: 01/01/19 Subject: Guselkumab (Tremfya ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationBiologic Therapy in Psoriasis: Navigating the Options
CLINICAL REVIEW Biologic Therapy in Psoriasis: Navigating the Options Cather McKay, MD; Katherine E. Kondratuk, BS; John P. Miller, BS; Brittany Stumpf, MD; Erin Boh, MD, PhD PRACTICE POINTS Psoriasis
More informationDetails of UNCOVER-2 and UNCOVER-3 Study Results Published in The Lancet
June 10, 2015 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Refer to: Immediately Tim Coulom; tim.coulom@lilly.com; 317-771-2241
More informationCombination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD
Combination Nonbiologic Therapy in Psoriasis Sushil Tahiliani, MBBS, MD Agenda Rationale Preferred and less preferred combination Morphology-specific preferred combinations Doses used in combinations Potential
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION IXEKIZUMAB (Taltz Eli Lilly Canada Inc.) Indication: Moderate to Severe Plaque Psoriasis Recommendation: The CADTH Canadian Drug Expert Committee
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationPsoriasis Pearls. Mark Lebwohl, MD
Psoriasis Pearls Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Psoriasis Pearls Pearl #1 Patients who can
More informationIxekizumab. Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A. Απρίλιοσ 2018 ΕΠΕΜΥ Πόρτο Χέλι
Ixekizumab Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A Απρίλιοσ 218 ΕΠΕΜΥ Πόρτο Χέλι ΣΑΜΑΣΗ-ΝΙΚΟ ΛΙΟΗ Καθηγ. Ρευματολογίας Ιατρική χολή Παν. Πατρών Ixekizumab Στοιχεία για το mab
More informationWhat is Enbrel? Key features
What is Enbrel? Enbrel (also known by its generic name etanercept) is a biologic medication approved in April 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #410: Psoriasis: Clinical Response to Systemic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes Meaningful Measure Area: Management of Chronic
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationHorizon Scanning Centre May Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524
Horizon Scanning Centre May 2014 Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524 This briefing is based on information available at the time of research and a limited literature
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264
Clinical Policy: (Stelara) Reference Number: CP.PHAR.264 Effective Date: 08/16 Last Review Date: 05/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationustekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:
Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationOTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone Patients with moderate to severe plaque psoriasis
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSynopsis (C0743T09 PHOENIX 2)
Monoclonal antibody () Synopsis ( PHOENIX 2) Protocol: EudraCT No.: 2005-003530-17 Title of the study: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy
More informationThe only biologic approved to treat SLE: now with multiple delivery options
The only biologic approved to treat SLE: now with multiple delivery options BENLYSTA (belimumab) Autoinjector SC Prefilled syringe IV Intravenous infusion Consider the options: visit Belimumab.com INDICATION
More informationUSTEKINUMAB. London New Drugs Group APC/DTC Briefing Document. May 2009
Page 1 London New Drugs Group APC/DTC Briefing Document USTEKINUMAB Contents Summary 1 Background 4 Clinical efficacy 5 Cost implications 9 Reference list 10 Appendices 11 Produced for the London New Drugs
More informationSTELARA. ustekinumab NEW ZEALAND DATA SHEET
1. PRODUCT NAME ustekinumab NEW ZEALAND DATA SHEET 45 mg solution for injection in vial. 90 mg solution for injection in vial. 45 mg solution for injection in pre-filled syringe. 90 mg solution for injection
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More informationSTELARA. ustekinumab NEW ZEALAND DATA SHEET
ustekinumab NEW ZEALAND DATA SHEET 1. PRODUCT NAME 45 mg solution for injection in vial. 90 mg solution for injection in vial. 45 mg solution for injection in pre-filled syringe. 90 mg solution for injection
More informationWhen researchers discovered in 1979 that the immunosuppressant
The Evolving Landscape of Psoriasis Treatment April W. Armstrong, MD, MPH,* Kenneth B. Gordon, MD, M. Alan Menter, MD, and Jashin J. Wu, MD Abstract The process of discovering new drugs for plaque psoriasis
More informationEvaluating Biologic Therapies for Psoriasis Strategies to Reduce Cost and Improve Patient Access and Outcomes
Evaluating Biologic Therapies for Psoriasis Strategies to Reduce Cost and Improve Patient Access and Outcomes Faculty William J. Cardarelli, PharmD Director of Pharmacy Revenue and Supply Atrius Health
More information